RecruitingNot ApplicableNCT07240441

Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)

Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT) - Multicenter, Prospective, Randomized Trial


Sponsor

MEDICOVER SP Z O.O.

Enrollment

220 participants

Start Date

Feb 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The EPISODE VT trial is designed to compare efficacy and safety of two modalities for interventional treatment - endocardial ablation and endo-epicardial ablation in a population of patients with post myocardial infarction (ICD 10 - I25.2) ventricular tachycardias (ICD 10 - I47.2), who are protected by an implantable cardioverter-defibrilator (ICD) and meet study inclusion criteria.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria10

  • Status after myocardial infarction (minimum 3 months before inclusion in the study).
  • Documented post-infarction VT or VF.
  • Implantable ICD (at least 2 weeks before ablation) or CRT-D (at least 2 months before ablation).
  • A history of at least one from below:
  • One or more high energy interventions.
  • Three or more adequate antitachycardia pacing therapies, including one symptomatic.
  • Three or more episodes of VT in 24 hours (interrupted by ATP or shock) - electrical storm.
  • Sustained VT recorded on ECG with a cycle length longer than the ICD detection threshold.
  • Age between 18 and 85 years.
  • Signed informed consent to participate in the study.

Exclusion Criteria12

  • Obesity with BMI \> 40 kg/m2.
  • Left ventricle ejection fraction \< 20%.
  • Pregnancy or breastfeeding.
  • Renal failure (eGFR \< 20 mL/min/1.73m2).
  • Fresh ballot thrombus in the left ventricle.
  • Suspicion of massive adhesions in the pericardium that may impede pericardial puncture.
  • Ablation of the post-infarction VT in the left ventricle in medical history.
  • Previous heart surgery.
  • Acute conditions that prevent ablation (including active infection, overt hyperthyroidism and others listed below).
  • Active neoplastic disease.
  • Heart failure with NYHA IV.
  • Life expectancy less than 12 months.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREEndocardial VT ablation

Post-myocardial infarction VT radiofrequency ablation using a standard endocardial approach

PROCEDUREEndo-epicardial VT ablation

Post-myocardial infarction VT radiofrequency ablation using an endo-epicardial approach with pericardial sac puncture preceded by CO2 insufflation


Locations(9)

Medicover Hospital

Warsaw, Masovian Voivodeship, Poland

Medical University of Warsaw

Warsaw, Masovian Voivodeship, Poland

National Institute of Cardiology

Warsaw, Masovian Voivodeship, Poland

University Hospital No. 1 in Bydgoszcz

Bydgoszcz, Poland

University Clinical Center based in Gdańsk

Gdansk, Poland

Independent Public Health Care Facility University Hospital in Krakow

Krakow, Poland

University Clinical Hospital in Poznań

Poznan, Poland

University Clinical Hospital No. 2 PUM in Szczecin

Szczecin, Poland

Grochowski Hospital named after Dr. Rafał Masztak, MD

Warsaw, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07240441


Related Trials